Medifast director Kiai Parsa buys $68,027 in company stock

On October 28, 2026, Medifast director Kiai Parsa acquired 5,557 shares of company stock, amounting to $68,027, as per a recent SEC filing. The purchase was made at an average price of $12.2417 per share, with the actual prices ranging between $12.205 and $12.25. The stock is currently trading at $12.15, close to the acquisition price.

Financial experts suggest that Medifast may be undervalued, with a Fair Value of $17.30, indicating possible upside potential from the current valuation. The director's indirect beneficial ownership of Medifast stock, through Steamboat Capital Partners Master Fund, LP and Steamboat Capital Partners II, LP, has increased to 712,891 shares and 20,428 shares respectively, following these transactions.

Notably, Mr. Parsa disclaims beneficial ownership of these securities except for his financial interest. Steamboat Capital Partners GP, LLC, serves as the managing member of the aforementioned funds, and Steamboat Capital Partners, LLC, is the investment adviser. Medifast's stock has generated a solid 12% return over the past six months.

Investors can explore further financial insights by accessing the comprehensive Pro Research Report for Medifast and 1,400+ other US equities. Recently, Medifast reported impressive financial results for Q3 2026, surpassing analyst expectations. The company posted an adjusted earnings loss of $0.19 per share, far better than the expected loss of $0.62 per share.

Revenue for the quarter reached $72.05 million, exceeding the forecasted $67.7 million, demonstrating that Medifast's turnaround initiatives are beginning to yield results. This positive performance has garnered investor interest as Medifast continues to demonstrate progress in its financial growth. This report was AI-generated with editorial review. For additional details, refer to the terms and conditions.